Diabetes Research and Clinical Practice - Volume 120 - Supplement 1

against postprandial oxidative stress and thus ameliorates

endothelial dysfunction (ED) in a population with high CV risk

such as metabolic syndrome and obesity. The aim of this

study is to investigatewhether a single administration of EVOO

restores endothelial function and induces changes on endo-

thelial physiology elements such as nitric oxide (NO) or

8-hydroxy-2

′

-deoxyguanosine (8-OHdG) in healthy subjects.

Fourteen apparently healthy subjects (10 men, 33 ± 8 years

old, BMI 21.8 ± 2.4) were recruited by advertisement and

informed consent was obtained from each subjects. The

subjects were divided into two groups to receive either EVOO

(30 mL) or processed butter (B: 30 g) in the morning after

an overnight fast following a randomized crossover design

with at least 1-week washout period. Brachial artery Flow-

Mediated Dilatation (FMD), a surrogate marker for vascular

endothelial function, was measured by use of a vascular

ultrasound system equipped with an edge-tracking system

and a pulsed Doppler flow velocimeter (Unex EF, Unex Co.,

Japan) before and 1, 2, 3 hours after an ingestion of either oil.

Blood samples were obtained from the antecubital vein at the

same time points as FMD for the measurements of serum

nitrite and nitrate (colorimetric method by Griess reagent) and

8-OHdG (ELISA).

Results:

Although FMD was significantly impaired after an

ingestion of B (10.2 ± 4.1% at baseline to 6.9 ± 3.8% after 3 hours,

P < 0.01), an ingestion of EVOO didn

’

t bring about such an

impairment of FMD (9.5 ± 3.2% at baseline to 8.2 ± 2.7% after 3

hours). Serum NO concentration decreased by processed B

(46.8 ± 35.4 μmol/L at baseline to 35.3 ± 24.6 μmol/L after 3

hours, P < 0.01) in contrast to no significant change after

EVOO ingestion. Furthermore, serum 8-OHdG concentration

increased by processed B (0.16 ± 0.03 ng/mL at baseline to

0.18 ± 0.05 ng/mL after 3 hours, P < 0.05) with no significant

change after EVOO ingestion.

Conclusion:

Our results clearly demonstrated that processed

B rich in saturated fatty acid caused post-prandial ED

through an enhancement of oxidative stress, which may lead

to future CV events. Unlike B, EVOO even composed of

fatty acid didn

’

t affect endothelial function probably due to

neutral effects on oxidative stress produced by its polyphenol

compounds.

PJ-53

Acarbose therapy and diagnosis of colorectal cancer in type 2

diabetes mellitus: A nationwide cohort study in Taiwan

Han-Wen LIU

, Yu-Ann FANG

, Chang-I CHEN

Chun-Jen CHANG

Division of Endocrinology and Metabolism,

Department of Internal Medicine, Wanfang Hospital, Taipei Medical

University,

Cancer Center, Wanfang Hospital, Taipei Medical

University, Taiwan

Background:

Acarbose, an alpha glucosidase inhibitor, is anti-

diabetic drug in clinical practice. It has been proposed

that acarbose therapy may have beneficial and putative

antineoplastic effect of the colon. However, there has been

few clinical study investigating this potential benefit. Acarbose

therapy is popular in Taiwan. We conducted a population-

based cohort study to investigate long-term acarbose use and

the incidence of colorectal cancer diagnosis in type 2 diabetes

patients.

Methods:

The study was conducted using the National Health

Insurance Research Database of Taiwan (1,000,000 randomly

sampled beneficiaries from the 25.68 million population in

Taiwan in 2005). Acarbose-use was defined as prescription of

acarbose for durations of at least 90 days every year continu-

ously until the study end or the date of diagnosis of colorectal

cancer. Patients prescribed with anti-diabetic drugs every year

continuously and never with acarbose were in the non-

acarbose group. Patients who were not prescribed with anti-

diabetic drugs continuously or who were not ever prescribed

with any anti-diabetic drugs were excluded. Patients with the

diagnosis of colon cancer or rectal cancer before or in 2005

were excluded. Total 21,337 type 2 diabetes patients were

included in the study. Follow-up duration was from 1 to 13

years.

Results:

The incidence rate of colorectal cancer diagnosis was

higher in the acarbose group than in non-acarbose group (598.2

vs. 434.9 per 100,000 person-years). The adjusted hazard ratio

(HR) was 1.97 (95% confidence interval [CI] 1.58

–

2.47). The

adjusted HR was 1.09 (95% CI 0.87

–

1.37) for acarbose use of 1

–

years and 2.76 (95% CI 1.33

–

5.73) for duration more than 8

years. Very high proportion of our cohort patients took

metformin (92.87%of acarbose group, 91.02%of non-acarbose).

Those who did not take metformin had similar incidence of

colorectal diagnosis in both groups (acarbose vs non-acarbose,

1010.1 vs. 1109.8 per 100,000 person-years), but those who

took metformin had significant difference (acarbose vs. non-

acarbose, 565.2 vs. 383.3 per 100,000 person-years; p < 0.001). In

our study cohort, metformin use was associated with lower

incidence of colorectal cancer diagnosis.

Conclusion:

Our finding suggests that acarbose in chronic

long-termuse might reduce the anti-colorectal cancer effect of

metformin. However, further clinical study is indicated.

PJ-54

Increased levels of soluble fibrin in human plasma in type 2

diabetic patients

Kazuo KAWASUGI

*, Tadashi YAMAMOTO

Toshiyuki HORIUCHI

, Mituo SHIMIZU

Department of

Hematology, Teikyo University School of Medicine,

Division on

Endocrinology and Metabolism, Tokyo Metropolitan Health Medical

Treatment Corporation Toshima Hospital,

Shimizu Clinic of Internal

Medicine, Japan

Background and aims:

A prothrombotic state characterized

by activation of the coagulation system has been implicated

in the pathogenesis of vascular complications in patients

with diabetes mellitus. Recently, soluble fibrin (SF) established

molecular marker reflecting hyper-coagulable states.

However, plasma levels of SF are unclear in type 2 diabetic

patients. Therefore, the current study aimed to evaluate

plasma levels of SF in type 2 diabetic patients.

Materials and methods:

The new onset type 2 diabetic

outpatients (hemoglobin A1c was higher than 9.2%) were

recruited from January 2014 through December 2015 (n = 53).

We measured plasma levels of SF, plasminogen activator

inhibitor-1 (PAI-1), D-dimer, prothrombin fragment 1 + 2

(F1 + 2), high sensitive C-reactive protein (hs-CRP) in the new

onset type 2 diabetic outpatients.

Results:

The average age of patients was 56.0 ± 14.6 years old

(range from 23

–

80 years old, 36 male, 17 female). Also, the

average hemoglobin A1c (HbA1c) of patients was 12.4 ± 2.0

(range from9.2

–

17.1%). We detected high plasma levels of SF in

about 55% of the new onset type 2 diabetic outpatients (range

from 5 to 33

g/mL). In healthy volunteers, plasma levels of SF

were less than 5

g/mL. Furthermore, the SF became less than

g/mL when HbA1c decreased by treatment of diabetes.

There was a positive correlation between plasma levels of SF

and hs-CRP. However, we did not find any difference plasma

levels of F1 + 2, PAI-1, and D-dimer in the new onset type 2

diabetic outpatients.

Conclusion:

These results suggest that new onset type 2

diabetic patients have a hyper-coagulable states. Also, in the

type 2 diabetic patients, the SF is thought to be useful as a

marker knowing whether coagulation system is activated.

PJ-55

The association between body mass index and cardiovascular

event in the Korean general population

So-hyeon HONG

, Jee-Young OH

, Young Sun HONG

Yeon-Ah SUNG

, Kyoung Ae KONG

, Hyejin LEE

Division of

Endocrinology and Metabolism, Department of Internal Medicine,

Poster Presentations / Diabetes Research and Clinical Practice 120S1 (2016) S65

–

S211

S208